AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 211 min read$MEDP

DAVENPORT FRED B JR sold $4.4M of MEDP

DAVENPORT FRED B JR sold 7,283 shares of Medpace Holdings, Inc. (MEDP) at $606.15 ($4.41M total) on 2026-08-19.

Original reporting
SEC EDGAR · DAVENPORT FRED B JR
Published Aug 21, 2026, 8:11 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 21, 2026, 8:37 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$MEDP
Bearish
medium confidence
Mentioned
$MEDP
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MEDPBearishLow
01

Why it matters

The sale represents a material divestiture by a director, potentially influencing investor perception.

02

Market read

Insider sell of $4.4M may prompt short interest and affect MEDP's near-term price.

03

What to watch

No accompanying news on earnings or clinical data to contextualize the sale.

Relevance 6/10Novelty 7/10Timing: after-market 2026-08-19

Background

Form 4 filing discloses insider transactions to the SEC.

Company-level read

Ticker impact

$MEDPBearishMedium confidence
Context

Director Fred B. Davenport Jr sold 7,283 shares of Medpace Holdings for $4.41M on 2026-08-19.

Expected impact

Possible short-term downside pressure.

Evidence & confidence

Director sale of $4.4M is material for a mid-cap biotech, suggesting insider concern.

Market effects

Sector

May raise questions about Medpace's pipeline or upcoming data releases.

Regional

Limited to US biotech sector.

Global

Minimal global impact.

Counterpoint

What could challenge this read

Insider sale could be routine portfolio rebalancing, not a red flag.

Key entities

  • Director
    Fred B. Davenport Jr

    Insider who sold shares.

  • Company
    Medpace Holdings, Inc.

    Biopharmaceutical contract research organization.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MEDP insider trading history →

Related articles

JUL 24
$ADVBMed

Top Biotech Gainers: ADVB Soars Over 200% In A Week, NVCR, MEDP Report Q2 Results, AGMB In Focus

Biotech gainers highlighted include Advanced Biomed (ADVB), up about 211% this week to $16.78, with no product sales and a recent SEC registration withdrawal. Novocure (NVCR) rose over 28% after Q2 results and raised 2026 revenue guidance to $710M-$725M. Medpace (MEDP) gained 14% on Q2 revenue of $707.3M and 2026 outlook. SciSparc (SPRC) and Agenus (AGEN) also rose; AgomAb (AGMB) gained on upcoming trial readouts.

rttnews.com7 min